- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07951021
Chemotherapy-Minimized Blank Microsphere Transarterial Embolization (BMS-TACE) Plus Low-Dose Lenvatinib, Iparomlimab and Tuvonralimab, and SBRT in Hepatocellular Carcinoma With Macrovascular Tumor Thrombus (TALES)
Chemotherapy-Minimized, Blank Microsphere-Based Transarterial Chemoembolization (BMS-TACE) Combined With Low-Dose Lenvatinib, Iparomlimab and Tuvonralimab, and Stereotactic Body Radiotherapy in Patients With BCLC Stage C Hepatocellular Carcinoma and Macrovascular Tumor Thrombus: A Single-Center, Single-Arm, Phase 2 Trial
Hepatocellular carcinoma (HCC) with macrovascular tumor thrombus carries a poor prognosis, and systemic therapy alone provides limited benefit in this population. This single-center, single-arm, phase 2 trial evaluates the efficacy and safety of a regimen combining chemotherapy-minimized, blank microsphere-based transarterial chemoembolization (BMS-TACE), low-dose lenvatinib, the anti-PD-1/CTLA-4 bispecific antibody iparomlimab and tuvonralimab, and stereotactic body radiotherapy (SBRT). In BMS-TACE, blank microspheres are the principal embolic agent and chemotherapy is used only as an adjunct at a fixed, minimal dose (doxorubicin 10 mg and lobaplatin 10 mg), in order to limit chemotherapy-related liver injury and systemic toxicity and to allow repeated embolization in patients with limited hepatic reserve. Forty-two participants with BCLC stage C HCC and tumor thrombus in the main portal vein or superior mesenteric vein (Vp3/Vp4), hepatic vein, or inferior vena cava, without extrahepatic metastases, will be enrolled. The primary endpoint is progression-free survival assessed by blinded independent central review using mRECIST.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Rationale. Patients with HCC and macrovascular invasion derive limited benefit from systemic therapy; in the Vp4 subgroup of IMbrave150, median overall survival with atezolizumab plus bevacizumab was 7.6 months. Locoregional therapy added to systemic therapy may improve tumor control, and radiotherapy is effective against tumor thrombus and is not limited by arterial blood supply. The investigators previously completed the TALEM trial (NCT05555316; Liver Cancer 2024;13:438-450), a prospective single-arm phase 2 study of BMS-TACE with low-dose chemotherapy plus low-dose lenvatinib and microwave ablation in large unresectable HCC, which reported a downstaging rate of 86.0%, an objective response rate of 93.0% by mRECIST, median progression-free survival of 14.7 months, and median overall survival of 36.4 months. In that study, myeloid-derived suppressor cells declined significantly and CXCR5-expressing CD4+ and CD8+ T cells increased significantly 24 hours after the first BMS-TACE, and participants with a decline in monocytic myeloid-derived suppressor cells had significantly better overall survival. These findings provide the mechanistic basis for adding an immune checkpoint inhibitor to BMS-TACE in the present trial.
Treatment. One cycle is defined as 21 days, matching the dosing interval of iparomlimab and tuvonralimab. Cycle 1 Day 1 is the day of the first BMS-TACE. Lenvatinib and iparomlimab and tuvonralimab both begin 3 to 7 days after the first BMS-TACE. BMS-TACE is repeated according to protocol-defined retreatment criteria, generally with two complete sessions followed by additional sessions as needed. SBRT is delivered with a minimum interval of 14 days from any BMS-TACE in either direction, and targets the tumor thrombus first; once the thrombus is devitalized, SBRT may be used to consolidate residual viable intrahepatic lesions. If a high-flow arterioportal or arteriohepatic venous shunt is identified at the first BMS-TACE that precludes safe embolization, SBRT to the tumor thrombus is brought forward to week 3 after the first BMS-TACE, and BMS-TACE is resumed after the shunt has diminished.
Assessments. Tumor assessments are performed by three-phase dynamic contrast-enhanced CT or dynamic contrast-enhanced liver MRI, using the same modality and protocol throughout for a given participant. Imaging is read centrally by two blinded independent radiologists using both mRECIST and RECIST 1.1, with adjudication by a third radiologist in case of disagreement; investigator assessment is performed in parallel for clinical decision-making and sensitivity analyses. Because BMS-TACE and SBRT act mainly by inducing tumor necrosis rather than shrinkage, and because pseudoprogression may occur with immune checkpoint inhibition, participants with a first radiological finding of progression but clinically stable disease may continue treatment and undergo confirmatory imaging 4 to 8 weeks later; when progression is confirmed, the event date is the date of the first documented progression.
Safety oversight. An independent Data and Safety Monitoring Committee reviews accumulating safety data, with a first meeting after the first 10 participants have completed one cycle and protocol-defined rules for holding enrollment.
Exploratory objectives. Peripheral blood is collected at baseline (1 to 3 days before the first BMS-TACE), 24 hours, 1 month and 3 months after the first BMS-TACE, and at disease progression or end of treatment, and immune cell subsets are characterized by flow cytometry and single-cell RNA sequencing. Pretreatment tumor tissue, and post-treatment tumor tissue obtained at conversion surgery or by biopsy at documented objective response or disease progression, is analyzed by single-cell RNA sequencing and spatial transcriptomics to characterize changes in the tumor microenvironment. The relationship of these changes with response and survival is explored.
Design rationale: de-escalation. Several phase 3 trials that added systemic therapy to TACE have reported a consistent pattern in which progression-free survival was met but overall survival was not. In LEAP-012, median progression-free survival was 14.6 versus 10.0 months (hazard ratio 0.66) while the interim overall survival hazard ratio was 0.80 (95% CI 0.57-1.11; p=0.087). In EMERALD-1, median progression-free survival was 15.0 versus 8.2 months (hazard ratio 0.77; p=0.032). In EMERALD-3, median progression-free survival was 13.0 versus 9.8 months (hazard ratio 0.70; p=0.0007), whereas median overall survival was 39.5 versus 34.7 months (hazard ratio 0.84; 95% CI 0.65-1.09; p=0.18). In TALENTACE, median TACE progression-free survival was 11.3 versus 7.0 months (hazard ratio 0.71; p=0.0089) with an interim overall survival hazard ratio of 0.96. The cost is recorded in the safety data: grade 3 or higher treatment-related adverse events occurred in 71% of participants in LEAP-012 versus 32% with TACE alone, and serious adverse events in 64% versus 23% in EMERALD-3, in which adding lenvatinib produced no incremental progression-free survival benefit (hazard ratio 0.94) yet raised discontinuation for adverse events from 21% to 36%.
This trial is therefore designed around de-escalation rather than intensification, on three premises: that toxicity truncates the time a participant remains on effective therapy and thereby erodes the advantage gained during first-line disease control; that cirrhosis is a concurrent disease in hepatocellular carcinoma, so tumour shrinkage obtained at the cost of liver injury removes eligibility for the subsequent therapy from which much of overall survival derives; and that agents added to an already adequate backbone tend to act additively rather than synergistically. Four design features follow. Embolization rather than chemotherapy is the principal antitumour mechanism, with a fixed minimal chemotherapy dose that may be omitted in later sessions according to response. Lenvatinib is given at a low dose, which both improves long-term tolerability and avoids the vascular pruning that would compromise repeated super-selective catheterization. SBRT carries the local intensity required for the tumour thrombus without adding systemic toxicity. Treatment is deliberately separated in time, both to limit overlapping toxicity and to preserve the T-cell proliferative response that concurrent cytotoxic therapy would blunt. Treatment exposure intensity, including lenvatinib relative dose intensity, cycles completed, and discontinuation due to adverse events, is examined in a protocol-specified exploratory analysis of whether this strategy achieves its intended effect.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Jinhua Huang, MD
- Número de teléfono: +86 135 4433 8551
- Correo electrónico: huangjh@sysucc.org.cn
Ubicaciones de estudio
-
-
Guangdong
-
Guangzhou, Guangdong, Porcelana, 510060
- Reclutamiento
- Sun Yat-sen University Cancer Center
-
Contacto:
- Jinhua Huang, MD
- Número de teléfono: +86 135 4433 8551
- Correo electrónico: huangjh@sysucc.org.cn
-
Contacto:
- Yi-Quan Jiang, M.D
- Número de teléfono: +8613544338551
- Correo electrónico: jiangyq@sysucc.org.cn
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Written informed consent
- Age 18 to 70 years, any sex
- Hepatocellular carcinoma confirmed histologically or cytologically, or diagnosed clinically according to AASLD criteria
- Child-Pugh score 7 or less
- BCLC stage C
- Tumor thrombus of the main portal vein or superior mesenteric vein (Vp3 or Vp4), or of the hepatic vein or inferior vena cava, without extrahepatic metastases
- At least one measurable lesion by mRECIST at the site of locoregional therapy
- ECOG performance status 0 or 1
- Adequate bone marrow function: neutrophils 1.5 x 10^9/L or above; hemoglobin 70 g/L or above; platelets 50 x 10^9/L or above; white blood cells 3.0 x 10^9/L or above
- Adequate liver function: serum albumin 28 g/L or above; total bilirubin 3.0 mg/dL or less; AST and ALT 5 times the upper limit of normal or less
- Adequate renal function: serum creatinine 1.5 times the upper limit of normal or less, or calculated creatinine clearance 50 mL/min or above
- Adequate coagulation function in participants not receiving anticoagulation: INR 2.3 or less
- Participants with active hepatitis B virus infection must be receiving antiviral therapy per local standard of care and be willing to continue it during the study
- Participants positive for hepatitis C virus antibody must be receiving anti-HCV therapy per local standard of care and be willing to continue it during the study
- Women of childbearing potential must have a negative urine pregnancy test before treatment and agree to use effective contraception during the study
Exclusion Criteria:
- Any prior antitumor therapy for hepatocellular carcinoma
- Known hypersensitivity or intolerance to any of the study drugs
- Concurrent malignancy other than hepatocellular carcinoma that is not cured, or another malignancy within the previous 3 years, except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix
- Uncontrolled clinically significant ascites not controlled by diuretics or paracentesis
- History of hepatic encephalopathy
- Clinically significant gastrointestinal bleeding within 30 days before enrollment, or bleeding from gastric or esophageal varices within the previous 3 months
- Uncorrectable coagulopathy, marked hematological abnormality, or evident bleeding tendency
- Significant cardiovascular disease: congestive heart failure, New York Heart Association class II or above, unstable angina, myocardial infarction, or arrhythmia requiring pharmacological treatment
- History of congenital long QT syndrome, or QT interval corrected by the Fridericia method greater than 480 ms
- Left ventricular ejection fraction below 45%
- Inadequately controlled blood pressure (systolic above 150 mmHg and/or diastolic above 100 mmHg)
- Urinary protein 1 g or more per 24 hours
- Previous organ transplantation
- Gastrointestinal malabsorption or any other condition that in the investigator's judgment may affect absorption of the study drug
- Pregnancy, lactation, or plan to become pregnant
- Active infection other than hepatitis B or C
- Currently receiving any other investigational drug or investigational medical device
- Any other condition that in the investigator's judgment makes the patient unsuitable for the study
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: BMS-TACE + low-dose lenvatinib + iparomlimab and tuvonralimab + SBRT
All participants receive chemotherapy-minimized, blank microsphere-based transarterial chemoembolization (BMS-TACE) on Cycle 1 Day 1. Low-dose lenvatinib and iparomlimab and tuvonralimab both start 3 to 7 days after the first BMS-TACE. Stereotactic body radiotherapy is delivered to the macrovascular tumor thrombus with a minimum interval of 14 days from any BMS-TACE in either direction. One cycle is 21 days. |
Visceral angiography of the celiac trunk, superior mesenteric artery and, as indicated, collateral arteries maps the arterial supply of the tumor and tumor thrombus and identifies arteriovenous shunting. A 2.8F microcatheter is placed super-selectively into tumor-feeding arteries by coaxial technique. A fixed, minimal-dose chemoemulsion (doxorubicin 10 mg and lobaplatin 10 mg in about 5 mL lipiodol) is injected slowly; chemotherapy may be omitted in later sessions according to tumor response, leaving blank-microsphere embolization alone. Blank microspheres are then delivered in ascending size order (40-120, 100-300, then 300-500 or 500-700 microns). The endpoint is contrast stasis over 3-5 cardiac cycles plus angiography 5-10 minutes later confirming loss of more than 90% of tumor staining. Imaging is repeated 4-6 weeks after each session; retreatment follows protocol-defined criteria. Participants generally receive two complete sessions. Lenvatinib 8 mg orally once daily for body weight 60 kg or above, or 4 mg orally once daily for body weight below 60 kg, started 3 to 7 days after the first BMS-TACE. Lenvatinib is withheld on the day of each BMS-TACE or SBRT and resumed 3 to 5 days afterwards provided the Child-Pugh score is 5 to 8; cumulative interruption does not exceed 3 weeks. Treatment continues until disease progression, unacceptable toxicity, or withdrawal of consent. Iparomlimab and tuvonralimab (QL1706), an anti-PD-1/anti-CTLA-4 bispecific antibody combination, 5 mg/kg intravenously every 3 weeks, infused over at least 30 minutes. Dosing starts 3 to 7 days after the first BMS-TACE and is separated from any BMS-TACE by at least 3 days. Treatment continues until disease progression or unacceptable toxicity. Immune-related adverse events are managed according to protocol-defined rules, including dose interruption, corticosteroid therapy and permanent discontinuation criteria.
Otros nombres:
Stereotactic body radiotherapy directed primarily at the macrovascular tumor thrombus. Simulation uses vacuum-bag or thermoplastic immobilization with 4D-CT or gated CT (slice thickness 3 mm or less). The prescription is 30 to 50 Gy in 5 to 10 fractions, individualized by tumor size and location, normal liver volume and Child-Pugh score: 40-50 Gy in 5 fractions when normal liver volume is 700 mL or more with Child-Pugh 5-6; 35-40 Gy in 5-8 fractions when normal liver volume is 500-700 mL or Child-Pugh is 7; and 30-40 Gy in 10 fractions when the target is within 1 cm of stomach, duodenum or colon. The prescription covers at least 95% of the planning target volume. Daily kV cone-beam CT image guidance is used with setup correction to within 3 mm. A minimum interval of 14 days separates SBRT and BMS-TACE in either direction. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Progression-free survival (PFS) by blinded independent central review (BICR) using mRECIST
Periodo de tiempo: From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months (14-month accrual plus 12 months of follow-up after the last participant is enrolled)
|
Time from Cycle 1 Day 1 (the day of the first BMS-TACE) to the first objective disease progression confirmed by blinded independent central review using mRECIST, or death from any cause, whichever occurs first. Participants without an event are censored at the last evaluable tumor assessment; participants starting a new anticancer therapy not specified in the protocol without documented progression are censored at that date; events occurring after two or more consecutively missed scheduled assessments are censored at the last evaluable assessment. RECIST 1.1 and investigator assessment are applied as sensitivity analyses. |
From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months (14-month accrual plus 12 months of follow-up after the last participant is enrolled)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Overall survival (OS)
Periodo de tiempo: From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
|
Time from Cycle 1 Day 1 to death from any cause. Participants alive are censored at the date last known to be alive. |
From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
|
|
Progression-free survival 2 (PFS2)
Periodo de tiempo: From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
|
Time from Cycle 1 Day 1 to the second objective disease progression documented during subsequent therapy, or death from any cause, whichever occurs first. |
From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
|
|
Objective response rate (ORR)
Periodo de tiempo: From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
|
Proportion of participants with a best overall response of complete or partial response by blinded independent central review using mRECIST, confirmed by repeat imaging at least 4 weeks later. |
From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
|
|
Disease control rate (DCR)
Periodo de tiempo: From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
|
Proportion of participants with a best overall response of complete response, partial response or stable disease by blinded independent central review using mRECIST. |
From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
|
|
Duration of response (DOR)
Periodo de tiempo: From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
|
Time from the first documented complete or partial response to the first documented disease progression or death from any cause. |
From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
|
|
Time to untreatable progression (TTUP)
Periodo de tiempo: From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
|
Time from Cycle 1 Day 1 to the date on which BMS-TACE is judged no longer feasible according to the protocol-defined criteria for technical infeasibility or BMS-TACE refractoriness. |
From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
|
|
Time to extrahepatic spread
Periodo de tiempo: From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
|
Time from Cycle 1 Day 1 to the first radiological documentation of extrahepatic metastasis. |
From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
|
|
Time to new vascular invasion
Periodo de tiempo: From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
|
Time from Cycle 1 Day 1 to the first radiological documentation of new macrovascular invasion. |
From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
|
|
Conversion rate to surgical resection
Periodo de tiempo: From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
|
Proportion of all enrolled participants judged by a multidisciplinary team to have become eligible for surgical resection, defined as successful downstaging, adequate future liver remnant and technical resectability. |
From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
|
|
Conversion rate to surgical resection or ablation
Periodo de tiempo: From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
|
Proportion of all enrolled participants judged eligible for surgical resection or ablation. Ablation eligibility is defined as 5 or fewer lesions, each 5 cm or smaller. |
From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
|
|
Change from baseline in EORTC QLQ-C30 scores
Periodo de tiempo: Baseline and Day 1 of each 21-day cycle from Cycle 2 until the end-of-treatment visit, up to approximately 26 months
|
Change from baseline in the functional scale, symptom scale and global health status/quality of life scores of the EORTC QLQ-C30 (version 3.0). Scores range from 0 to 100; for functional scales and global health status, higher scores indicate better functioning, whereas for symptom scales higher scores indicate worse symptoms. |
Baseline and Day 1 of each 21-day cycle from Cycle 2 until the end-of-treatment visit, up to approximately 26 months
|
|
Incidence and severity of adverse events and procedure-related complications
Periodo de tiempo: From Cycle 1 Day 1 (each cycle is 21 days) to 30 days after the last dose of study treatment
|
Incidence and severity of adverse events, serious adverse events, and BMS-TACE- and SBRT-related procedural complications, graded by CTCAE version 5.0. Major complications are defined as those requiring escalation of care, prolonged hospitalization, readmission, or resulting in permanent sequelae. |
From Cycle 1 Day 1 (each cycle is 21 days) to 30 days after the last dose of study treatment
|
|
Change from baseline in EORTC QLQ-HCC18 scores
Periodo de tiempo: Baseline and Day 1 of each 21-day cycle from Cycle 2 until the end-of-treatment visit, up to approximately 26 months
|
Change from baseline in the symptom scale scores of the EORTC QLQ-HCC18 hepatocellular carcinoma-specific module. Scores range from 0 to 100; higher scores indicate worse symptoms. |
Baseline and Day 1 of each 21-day cycle from Cycle 2 until the end-of-treatment visit, up to approximately 26 months
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from baseline in the percentage of myeloid-derived suppressor cells (MDSCs) in peripheral blood, measured by flow cytometry
Periodo de tiempo: Baseline (1-3 days before the first BMS-TACE); 24 hours, 1 month and 3 months after the first BMS-TACE; and at disease progression or end of treatment, up to approximately 26 months.
|
Percentage of CD11b+CD33+HLA-DR- myeloid-derived suppressor cells among peripheral blood mononuclear cells, measured by flow cytometry. |
Baseline (1-3 days before the first BMS-TACE); 24 hours, 1 month and 3 months after the first BMS-TACE; and at disease progression or end of treatment, up to approximately 26 months.
|
|
Change from baseline in the percentage of CXCR5+ cells among peripheral blood CD8+ T cells, measured by flow cytometry
Periodo de tiempo: Baseline (1-3 days before the first BMS-TACE); 24 hours, 1 month and 3 months after the first BMS-TACE; and at disease progression or end of treatment, up to approximately 26 months.
|
Percentage of CXCR5-expressing cells among CD3+CD8+ T cells in peripheral blood mononuclear cells, measured by flow cytometry. |
Baseline (1-3 days before the first BMS-TACE); 24 hours, 1 month and 3 months after the first BMS-TACE; and at disease progression or end of treatment, up to approximately 26 months.
|
|
Change from baseline in the percentage of CXCR5+ cells among peripheral blood CD4+ T cells, measured by flow cytometry
Periodo de tiempo: Baseline (1-3 days before the first BMS-TACE); 24 hours, 1 month and 3 months after the first BMS-TACE; and at disease progression or end of treatment, up to approximately 26 months.
|
Percentage of CXCR5-expressing cells among CD3+CD4+ T cells in peripheral blood mononuclear cells, measured by flow cytometry. |
Baseline (1-3 days before the first BMS-TACE); 24 hours, 1 month and 3 months after the first BMS-TACE; and at disease progression or end of treatment, up to approximately 26 months.
|
|
Change from baseline in the proportions of peripheral blood immune cell subsets, measured by single-cell RNA sequencing
Periodo de tiempo: Baseline (1-3 days before the first BMS-TACE); 24 hours, 1 month and 3 months after the first BMS-TACE; and at disease progression or end of treatment, up to approximately 26 months.
|
Percentage of each immune cell subset (including CD8+ and CD4+ T-cell states, natural killer cells, monocytes and myeloid-derived suppressor cells) among all peripheral blood mononuclear cells, identified by single-cell RNA sequencing. |
Baseline (1-3 days before the first BMS-TACE); 24 hours, 1 month and 3 months after the first BMS-TACE; and at disease progression or end of treatment, up to approximately 26 months.
|
|
Change in the proportions of immune and stromal cell subsets in tumor tissue, measured by single-cell RNA sequencing
Periodo de tiempo: Baseline (pretreatment tumor biopsy) and at post-treatment tumor sampling (conversion surgery, or biopsy at documented objective response or disease progression), assessed up to approximately 26 months
|
Percentage of each cell subset (including T-cell, myeloid, endothelial and fibroblast subsets) among all cells sequenced from tumor tissue, compared between pretreatment and post-treatment samples. Post-treatment samples are obtained from participants with objective response and from those with stable or progressive disease. |
Baseline (pretreatment tumor biopsy) and at post-treatment tumor sampling (conversion surgery, or biopsy at documented objective response or disease progression), assessed up to approximately 26 months
|
|
Change in the spatial cell-type composition of tumor tissue, measured by spatial transcriptomics
Periodo de tiempo: Baseline (pretreatment tumor biopsy) and at post-treatment tumor sampling (conversion surgery, or biopsy at documented objective response or disease progression), assessed up to approximately 26 months
|
Percentage of spatial transcriptomic capture spots assigned to each cell type by cell-type deconvolution, in the tumor core and at the invasive margin, compared between pretreatment and post-treatment tumor samples. |
Baseline (pretreatment tumor biopsy) and at post-treatment tumor sampling (conversion surgery, or biopsy at documented objective response or disease progression), assessed up to approximately 26 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Jinhua Huang, MD, Sun Yat-Sen University Cancer Center
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias por sitio
- Neoplasias
- Neoplasias por tipo histológico
- Neoplasias del Sistema Digestivo
- Enfermedades del Sistema Digestivo
- Enfermedades del HIGADO
- Neoplasias Glandulares y Epiteliales
- Adenocarcinoma
- Neoplasias Hepaticas
- Carcinoma
- Carcinoma Hepatocelular
- Técnicas de investigación
- Terapéutica
- Procedimientos quirúrgicos, operativo
- Radioterapia
- Técnicas estereotáxicas
- Procedimientos neurociruúrgicos
- Radiocirugía
- lenvatinib
Otros números de identificación del estudio
- SL-B2025-808-04
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
De-identified individual participant data underlying the published results, together with the data dictionary, will be shared with investigators whose proposed use of the data has been approved by the study steering group.
Marco de tiempo para compartir IPD
Beginning 6 months and ending 36 months after publication of the primary results.
Criterios de acceso compartido de IPD
Requests should be submitted in writing to the principal investigator. Proposals will be reviewed by the study steering group, and approved requesters must sign a data use agreement before data are released.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
- CÓDIGO_ANALÍTICO
- RSC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .